Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus / COVID-19 Pandemic -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (20698)	5/6/2022 3:33:41 PM
From: Thomas M.	1 Recommendation Recommended By Savant Respond to of 22867

Ed Mills, the senior author of that study: I actually think it is quite positive. I presented this a couple weeks ago at the NIH Collaboratory Rounds and, if they listened, I advocate that actually, there is a clear signal that IVM works in COVID patients, just that our study didn’t achieve significance. I really don’t view our study as negative and, also in that talk, you will hear me retract previous statements where I had been previously negative. I think if we had continued randomizing a few hundred more patients, it would have likely been significant. stevekirsch.substack.com Tom

To: Glenn Petersen who wrote (20698)	10/19/2022 11:04:41 PM
From: Thomas M.	1 Recommendation Recommended By Stormwatch17 Respond to of 22867

It appears that Together Trial is a fraud. They've been hiding their data for 14 months. The FDA ain't buying it. FDA denied the request for a pre-EUA meeting. Citing its concerns about the conduct of the TOGETHER study, FDA concluded that any authorization request based on these data is unlikely to meet the statutory criteria for issuance of an EUA in the current context of the pandemic. prnewswire.com Last month Eiger gave a hint: Following a cooperative and extensive pre-EUA information exchange with FDA regarding the Phase 3 TOGETHER study of peginterferon lambda for COVID-19, the agency has indicated that it is not yet able to determine whether the criteria for the submission of an application and issuance of an EUA are likely to be met. FDA has indicated that it will consider any new information and data from the TOGETHER study to support an EUA. ir.eigerbio.com The fraud was expected, based on who was backing and promoting the trial, as well as the numerous "tricks" the yengaged in: sneaky trick to underdose patients - ordered them to take Ivermectin without food - reduces uptake by up to 80% drug group administered during deadly Gamma surge, but not the control group changed endpoints after trial was underway advertised as randomized, but apparently not Tom